These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22233646)

  • 1. Hypothesis testing in high-throughput screening for drug discovery.
    Prummer M
    J Biomol Screen; 2012 Apr; 17(4):519-29. PubMed ID: 22233646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the prediction of statistical parameters in high-throughput screening using resampling techniques.
    Ilouga PE; Hesterkamp T
    J Biomol Screen; 2012 Jul; 17(6):705-12. PubMed ID: 22460175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.
    Shun TY; Lazo JS; Sharlow ER; Johnston PA
    J Biomol Screen; 2011 Jan; 16(1):1-14. PubMed ID: 21160066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cheminformatics approaches to analyze diversity in compound screening libraries.
    Akella LB; DeCaprio D
    Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings.
    Wu Z; Liu D; Sui Y
    J Biomol Screen; 2008 Feb; 13(2):159-67. PubMed ID: 18216390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing Bayesian thinking to high-throughput screening for false-negative rate estimation.
    Wei X; Gao L; Zhang X; Qian H; Rowan K; Mark D; Peng Z; Huang KS
    J Biomol Screen; 2013 Oct; 18(9):1121-31. PubMed ID: 23720569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Interweaving of Cheminformatics and HTS.
    Kümmel A; Parker CN
    Methods Mol Biol; 2011; 672():435-57. PubMed ID: 20838979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hit finding: towards 'smarter' approaches.
    Langer T; Hoffmann R; Bryant S; Lesur B
    Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced HTS hit selection via a local hit rate analysis.
    Posner BA; Xi H; Mills JE
    J Chem Inf Model; 2009 Oct; 49(10):2202-10. PubMed ID: 19795815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method with flexible and balanced control of false negatives and false positives for hit selection in RNA interference high-throughput screening assays.
    Zhang XD
    J Biomol Screen; 2007 Aug; 12(5):645-55. PubMed ID: 17517904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving detection of rare biological events in high-throughput screens.
    Murie C; Barette C; Button J; Lafanechère L; Nadon R
    J Biomol Screen; 2015 Feb; 20(2):230-41. PubMed ID: 25190066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin.
    Jenkins JL; Kao RY; Shapiro R
    Proteins; 2003 Jan; 50(1):81-93. PubMed ID: 12471601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of high-throughput mass spectrometry to reduce false positives in protease uHTS screens.
    Adam GC; Meng J; Rizzo JM; Amoss A; Lusen JW; Patel A; Riley D; Hunt R; Zuck P; Johnson EN; Uebele VN; Hermes JD
    J Biomol Screen; 2015 Feb; 20(2):212-22. PubMed ID: 25336354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates.
    Liu Y; Beresini MH; Johnson A; Mintzer R; Shah K; Clark K; Schmidt S; Lewis C; Liimatta M; Elliott LO; Gustafson A; Heise CE
    J Biomol Screen; 2012 Feb; 17(2):225-36. PubMed ID: 21940710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.
    Li Q; Chen C; Kapadia A; Zhou Q; Harper MK; Schaack J; LaBarbera DV
    J Biomol Screen; 2011 Feb; 16(2):141-54. PubMed ID: 21297102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothesis-driven screening.
    Schopfer U; Engeloch C; Höhn F; Mees H; Leeds J; Glickman F; Scheel G; Ferrand S; Fekkes P; Pfeifer M
    Methods Mol Biol; 2009; 575():297-316. PubMed ID: 19727621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Automatic Quality Control Pipeline for High-Throughput Screening Hit Identification.
    Zhai Y; Chen K; Zhong Y; Zhou B; Ainscow E; Wu YT; Zhou Y
    J Biomol Screen; 2016 Sep; 21(8):832-41. PubMed ID: 27313114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.
    Heeres JT; Hergenrother PJ
    Chem Soc Rev; 2011 Aug; 40(8):4398-410. PubMed ID: 21140010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.